bg_2

Whitepapers

White Paper 1 – HyperQ™ Technology
Occlusion of the coronary arteries that supply oxygenated blood to the heart muscle is referred to as ischemic heart disease (IHD). Traditional ECG analysis is performed in the 0.05 – 100Hz frequency range. However, a significant body of evidence accumulated during recent years indicates that higher frequency spectral components of the ECG signal contain valuable information for the detection of IHD. Studies published by Prof. Shimon Abboud, BSP’s chief scientist, and Dr. Amir Beker, BSP’s founder, have shown that the presence of ischemic pathologies in the heart is highly correlated with specific changes in the high-frequency spectral components of the ECG.
More…

* * *

White Paper 2 – Diagnosis of Ischemic Heart Disease using High Frequency ECG, Literature Review
Several attempts have been made by researchers to expand the diagnostic capabilities of the electrocardiogram (ECG). One of the most promising methodologies to date is the analysis of the high frequency spectral components of the QRS complex (HFQRS). Investigation of changes in the HFQRS in multiple clinical conditions revealed a close relation between HFQRS and myocardial ischemia.
More…

* * *

White Paper 3 – Clinical Studies
BSP’s novel, clinical implementation of HFQRS analysis is provided in The HyperQ™ System. The scientific basis of the HyperQ System is based on numerous research studies that have been published in leading cardiology journals during the last two decades. Extensive research efforts, including computer modeling, animal experiments as well as dedicated studies in humans, provide a sound scientific basis for the ability to identify myocardial ischemia using analysis of the high-frequency components in the mid-QRS complex of the ECG.
More…

* * *

White Paper 4 – The Economic Benefit of the HyperQ™ Stress Test in the Diagnosis and Management of Coronary Heart Disease
Coronary Heart Disease (CHD) is a major healthcare problem worldwide, being the leading cause of death and imposing an enormous global economic burden. In the US alone, there are 17.6 million CHD patients. The ensuing direct and indirect costs in the US are estimated at $177 billion in 2010. Accurate early diagnosis of CHD plays a crucial role in improving the prognosis of patients and in reducing the long-term costs of medical treatment. In this respect, conventional exercise ECG testing (EET) is known to be limited by low diagnostic accuracy, often leading to expensive cardiac imaging tests and ultimately also invasive coronary angiography. The HyperQ™ stress test, based on analysis of high-frequency QRS components of the ECG, provides a highly-accurate index of demand ischemia, which significantly improves upon the diagnostic performance of EET. This white paper describes the economic benefits of incorporating the HyperQ™ stress test into the routine diagnosis and management of CHD patients. The results suggest that the potential immediate annual
savings amount to $1.2B in the US.
More…

* * *

White Paper 5 – Resting HyperQ: Diagnosis and Monitoring of Patients with Acute Coronary Syndrome
BSP is developing a new line of products, based on HyperQ™ technology, for highly-accurate early detection and monitoring of acute myocardial ischemia. Relying upon sound scientific foundations as well as promising results of on-going clinical studies, it is anticipated that these products will provide valuable new tools for a variety of clinical applications, including resting ECG, bedside monitoring and home telehealth. This whitepaper describes the technology and the clinical data supporting its efficacy.
More…

* * *